Buprenorphine Microdosing Cross Tapers: A Time for Change

Buprenorphine is a partial opioid agonist that is Food and Drug Administration (FDA) approved to treat chronic pain and opioid use disorder (OUD). The national prescribing guidelines in the United States (US) recommend that patients transitioning from full opioid agonists to buprenorphine first unde...

Descripción completa

Detalles Bibliográficos
Autores principales: Raheemullah, Amer, Benhamou, Ori-Michael, Kuo, Jamie, Lembke, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Viewpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9778657/
https://www.ncbi.nlm.nih.gov/pubmed/36554317
http://dx.doi.org/10.3390/ijerph192416436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9778657/
https://www.ncbi.nlm.nih.gov/pubmed/36554317
http://dx.doi.org/10.3390/ijerph192416436

Ejemplares similares